Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics' Q3 Profit Erased on Increased Tax Expense

NEW YORK (GenomeWeb News) — Strategic Diagnostics said Wednesday that a $100,000 tax adjustment has erased its entire third-quarter profit.
 
The company’s original earnings report for the three months ended Sept. 30, disclosed Nov. 1, showed a $100,000 profit, which was a decline from the $332,000 it earned during the comparable period one year earlier.
  
The $100,000 profit included a tax expense of $175,000, which included an adjustment designed to reconcile a tax provision for the year ended Dec. 31, 2006, with the actual filing of the 2006 tax return. When Strategic Diagnostics issued its earnings report Nov. 1 it said that "a review of this additional tax expense was continuing." 
 
On Wednesday, the company said it has completed the review and raised its tax expense for the period to $275,000, which in turn erased its profit for the third quarter.
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.